How SIRPalpha Pushes Triple-Negative Breast Cancer to Brain

What if a protein famous for telling immune cells to stand down is quietly helping cancer colonize the brain? That provocative idea comes from researchers at Wake Forest University School of Medicine, who traced a troubling pattern in triple-negative breast cancer.

Triple-negative breast cancer, the form that refuses to wear the usual molecular name tags, already carries a higher risk of spreading to the brain—a site where doctors have few reliable weapons. The Wake Forest team found that a protein called SIRPalpha, long studied for its role on immune cells, also turns up inside tumor cells and rewires how they behave and how the brain reacts to them.

Looking at patient tumors and large cancer datasets, the investigators saw more SIRPalpha in triple-negative tumors, particularly those that had metastasized to the brain. Higher levels tracked with worse outcomes. Correlation is not causation, of course, but it was a red flag that demanded follow-up in the lab.

So they moved to preclinical models that mimic breast cancer’s path to the brain. When SIRPalpha was reduced or blocked, tumors grew more slowly, the amount of cancer in the brain fell, and the arrival of metastatic lesions was delayed. The blockade also reversed some of the tricks tumor cells use to slip past immune surveillance.

Blocking SIRPalpha slowed tumor growth and reduced brain metastases in preclinical models.

The team dug deeper. Tumor cells with high SIRPalpha cranked up production of fibronectin, an extracellular scaffold protein. Over time, repeated exposure to fibronectin appears to blunt microglia, the brain’s resident immune sentries, making them less likely to mount an inflammatory attack. In plain terms, the tumor remodels its neighborhood to become more hospitable—an engineered safe house.

There was another twist inside the cancer cell. High SIRPalpha levels correlated with fragmented mitochondria, a state produced by mitochondrial fission. Fragmented mitochondria are not merely a biochemical curiosity; they seem to help cancer cells move and invade. Think of it as swapping out a heavy winter coat for lighter running gear.

Most experimental therapies aimed at the CD47-SIRPalpha axis have focused on immune cells, trying to lift the brakes that stop macrophages from eating tumor cells. These new results suggest an additional angle: target SIRPalpha inside the tumor itself to interfere with its metabolic wiring and its ability to reprogram the brain microenvironment. That could amplify the benefit of existing immunotherapies, if it proves safe and effective.

The work remains preclinical. The authors plan to map precisely how SIRPalpha signals inside cancer cells, test whether it can be targeted without harming normal tissue, and explore combination approaches that might prevent or treat brain metastases from triple-negative breast cancer.

It is a reminder that cancer is not just a collection of rogue cells but an active architect of its surroundings. If we can learn how to dismantle those constructions, we may blunt one of the most feared journeys a tumor can make.